A number of other firms have also recently commented on OSUR. Analysts at RBC Capital (NYSE: RY) initiated coverage on shares of OraSure Technologies in a research note to investors on Tuesday, April 10th. They set an “outperform” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of OraSure Technologies in a research note to investors on Tuesday, March 27th. They set an “outperform” rating and a $15.00 price target on the stock. Finally, analysts at McNicoll Lewis & Vlak upgraded shares of OraSure Technologies to a “buy” rating in a research note to investors on Wednesday, March 21st.
OraSure Technologies traded down 3.14% on Thursday, hitting $10.18. OraSure Technologies has a 52-week low of $6.29 and a 52-week high of $11.78. The company’s market cap is $486.7 million.
The company last announced its quarterly results on Wednesday, May 2nd. It reported ($0.07) earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.09) EPS by $0.02. The company’s quarterly revenue was up 20.1% on a year-over-year basis. Analysts expect that OraSure Technologies will post $-0.02 EPS next quarter.
OraSure Technologies, Inc. is engaged in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its oral fluid technologies, as well as other diagnostic products, including immunoassays and other in-vitro diagnostic tests that are used on other specimen types, and other medical devices used for the removal of benign skin lesions by cryosurgery or freezing.